Clinical and translational radiation oncology 2022 Nov 21
TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer.
ABSTRACT
•There is a lack of prospective level I evidence for the use of PBT for most adult cancers including oropharyngeal squamous cell carcinoma (OPSCC).•TORPEdO is the UK's first PBT clinical trial and aims to determine the benefits of PBT for OPSCC.•Training and support has been provided before and during the trial to reduce variations of contouring and radiotherapy planning.•There is a strong translational component within TORPEdO. Imaging and physics data along with blood, tissue collection will inform future studies in refining patient selection for IMPT.
Related Questions
A recent randomized trial showed equivalent rates of disease control, with an "unexpected improvement in survival outcomes" with IMPT per the authors'...
New answer by Radiation Oncologist at Genesis Healthcare Partners- San Diego (January 8, 2026)
Treatment at a center of excellence with high volumes and/or a well-trained, experienced radiation oncologist and team is more important than proton or photon discussion, IMHO...